Gold(I) complex of 1,1′-bis(diphenylphosphino) ferrocene–quinoline conjugate : a virostatic agent against HIV-1
Loading...
Date
Authors
Gama, Ntombenhle Hlengiwe
Kumar, Kamlesh
Ekengard, Erik
Haukka, Matti
Darkwa, James
Nordlander, Ebbe
Meyer, Debra
Journal Title
Journal ISSN
Volume Title
Publisher
Springer
Abstract
HIV infection is known for replication in proliferating CD+ T-cells. Treatment of these cells
with cytostatic (anti-proliferation) compounds such as hydroxyurea interferes with the cells’s
ability support HIV replication. Combinations of such cytostatic compounds with proven
anti-retroviral drugs (like ddI) are known as virostatic , and have been shown to aid in the
control of the infection. The use of two different drugs in virostatic combinations however,
carries the risk of adverse effects including drug-drug interactions, which could lead to
augmented toxicities and reduced efficacy. Here, a novel digold(I) complex of ferrocenequinoline
(3) was investigated for cytostatic behaviour as well as anti-viral activity which if
demonstrated would eliminate concerns of drug-drug interactions. The complex was
synthesized and characterized by NMR, FT-IR and mass spectroscopy and the molecular
structure was confirmed by X-ray crystallography. Bio-screening involved viability dyes, real
time electronic sensing and whole virus assays. The complex showed significant (p = 0.0092)
inhibition of virus infectivity (83%) at 10 ug/mL. This same concentration caused cytostatic
behaviour in TZM-bl cells with significant (p<0.01) S and G2/M phase cell cycle arrest.
These data supports 3 as a virostatic agent, possessing both anti-viral and cytostatic
characteristics.
Description
Keywords
HIV infection, Hydroxyurea interferes, Cytostatic (anti-proliferation) compounds, Human immunodeficiency virus (HIV)
Sustainable Development Goals
Citation
Gama, N, Kumar, K, Ekengard, E, Haukka, M, Darkwa, J, Nordlander, E & Meyer, D 2016, 'Gold(I) complex of 1,1′-bis(diphenylphosphino) ferrocene–quinoline conjugate : a virostatic agent against HIV-1', BioMetals, vol. 29, no. 3, pp. 389-397